Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mirdametinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SpringWorks Publishes Phase 2b ReNeu Results in Clinical Oncology
    SpringWorks Publishes Phase 2b ReNeu Results in Clinical Oncology

    11 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/11/2978166/0/en/SpringWorks-Therapeutics-Announces-Publication-of-the-Pivotal-Phase-2b-ReNeu-Trial-Evaluating-Mirdametinib-in-Adults-and-Children-with-NF1-PN-in-the-Journal-of-Clinical-Oncology.html

    GLOBENEWSWIRE
    11 Nov 2024
    Share Share
    SpringWorks Submits NDA For Mirdametinib In NF1-PN Treatment
    SpringWorks Submits NDA For Mirdametinib In NF1-PN Treatment

    01 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/01/2906535/0/en/SpringWorks-Therapeutics-Completes-Submission-of-New-Drug-Application-to-the-FDA-for-Mirdametinib-for-the-Treatment-of-Children-and-Adults-with-NF1-PN.html

    GLOBENEWSWIRE
    01 Jul 2024
    Share Share
    Springworks Data Presentation: 2024 Asco Annual Meeting Scheduled
    Springworks Data Presentation: 2024 Asco Annual Meeting Scheduled

    23 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/23/2887711/0/en/SpringWorks-Therapeutics-Announces-Data-to-be-Presented-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    23 May 2024
    Share Share
    SpringWorks Abstracts Accepted for ASCO 2024 Presentation
    SpringWorks Abstracts Accepted for ASCO 2024 Presentation

    24 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/24/2868970/0/en/SpringWorks-Therapeutics-Announces-Abstracts-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    24 Apr 2024
    Share Share
    SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib
    SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib

    04 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/04/2839366/0/en/SpringWorks-Therapeutics-Initiates-Rolling-Submission-of-New-Drug-Application-to-the-FDA-for-Mirdametinib-for-the-Treatment-of-Children-and-Adults-with-NF1-PN.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    SpringWorks Announces Positive Results from Phase 2b ReNeu Trial of Mirdametinib
    SpringWorks Announces Positive Results from Phase 2b ReNeu Trial of Mirdametinib

    16 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/16/2781664/0/en/SpringWorks-Therapeutics-Announces-Positive-Topline-Results-from-the-Phase-2b-ReNeu-Trial-of-Mirdametinib-in-NF1-PN.html

    GLOBENEWSWIRE
    16 Nov 2023
    Share Share